May 26 (Reuters) - The U.S. Food and Drug administration on Wednesday gave an emergency use authorization to the COVID-19 antibody treatment developed by Vir Biotechnology Inc and GlaxoSmithKline. (https://bit.ly/3uorQZ8) (Reporting by Amruta Khandekar; Editing by Shounak Dasgupta)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,654 GBX | +0.18% | +4.06% | +14.09% |
10:51am | GSK: FDA priority review for endometrial cancer | CF |
10:14am | GSK's Jemperli with chemotherapy accepted for priority review by FDA | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.09% | 83.92B | |
+27.92% | 672B | |
+27.22% | 570B | |
-4.59% | 360B | |
+16.38% | 321B | |
+9.39% | 300B | |
+7.40% | 217B | |
+6.21% | 199B | |
-8.79% | 204B | |
-8.58% | 149B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- GlaxoSmithKline : U.S. FDA gives emergency use approval to GSK-Vir COVID-19 antibody drug